Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
Ebixa approved for the treatment of moderate Alzheimer disease in Europe
November 18th, 2005
The European health authorities have approved Ebixa (memantine) for the treatment of moderate Alzheimer disease. Ebixa is already the leading drug for the treatment of severe stages of Alzheimer disease, according to H. Lundbeck, A/S. Following the extension of the indication for the treatment of moderate Alzheimer disease - an area that has so far been restricted to one class of drugs; the so-called acetylcholinesterase inhibitors (AchEI) - Ebixa is now the only approved drug for the treatment of moderate, moderately severe, and severe Alzheimer disease, the company says. The approval does not cover the very early mild stage of Alzheimer disease. ...
Source: Drug Week (2005-11-18)
|
